Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. saw a decline in its stock today, contrasting with the broader market's performance. Despite recent losses over the week and month, the company has shown strong growth over three years and maintains a solid financial position with consistent positive results.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. saw a significant stock decline today, contrasting with the broader market. Over the past week and month, the stock has experienced notable decreases, yet the company has shown strong long-term growth and maintains a solid financial position with consistent positive results and a commitment to shareholder returns.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. faced a notable decline in stock value, contrasting with the modest gain of the China Shanghai Composite. Despite recent challenges, the company has shown resilience with positive long-term performance and strong financial metrics, including a high return on equity and consistent quarterly profits.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. saw a notable stock price increase on May 29, 2026, reaching an intraday high. The company has shown consistent growth, with significant increases over the past three and five years, alongside strong financial metrics and a solid operational foundation.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. faced a significant decline in its stock today, marking an 8.08% decrease over the past week and a 20.36% drop in the last month. Despite these challenges, the company has shown impressive long-term growth and maintains a strong financial position.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. faced a significant stock decline today, contrasting with the broader market's modest gain. Over the past month, the company's stock has dropped considerably, although it has shown strong long-term performance, with a notable annual return and consistent positive financial results.

Sunshine Guojian Pharmaceutical has recently adjusted its evaluation, reflecting strong market performance. The company reported a record operating cash flow of CNY 2,979.1 million and a return on capital employed of 15.87%. Over the past year, it achieved a profit increase of 131.7% and outperformed the broader market significantly.